Notably, the World Health Organization (WHO) incorporated the distinction between mutated and wild-type TP53 in specific brain tumors [19,20], and TP53 mutational status can have varying implications for different medulloblastoma groups, divided into sonic hedgehog (SHH)-activated and TP53-wild type, and SHH-activated and TP53-mutant, for example [21]. This evidence concerns the gene SHH and brain neoplasm.